- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01303926
Quality of Life Comparison in Advanced Non-squamous Non Small Cell Lung Cancer (ERACLE)
Induction Pemetrexed and Cisplatin Followed by Pemetrexed as Maintenance vs Carboplatin-paclitaxel and Bevacizumab Followed by Bevacizumab as Maintenance:Multicenter Randomized Phase III Study in Patients With Advanced Non-Squamous Non Small-cell Lung Cancer: a Quality of Life Oriented Phase III Trial of the GOIM
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
The study aims primarily to verify the null hypothesis that between the two schemes under consideration there is no minimal interesting difference (MID) (i.e. a difference of clinical interest) after initial 3 months of maintenance.EuroQ5D (EQ5D) questionnaire total score and EQ5D visual analog scale (VAS)are validated and very simple to be administered.The statistical hypothesis tests described above are performed with t-test for unpaired data (or equivalent non-parametric, pending verification of normality of distribution by Shapiro-Wilk test), with alpha error = 0.05 (2-sided). It is assumed that:
- about 20% of randomized patients experienced a progression of disease before the time of evaluation of the primary endpoint, and that
- this eventuality was not significantly different between the two treatments. The total sample to be enrolled for this study will then be increased to 118 patients [(49 +49) +20%)]
Studietyp
Inskrivning (Förväntat)
Fas
- Fas 3
Kontakter och platser
Studieorter
-
-
-
Napoli, Italien
- National Cancer Institute "G. Pascale" Thoracic Dept.
-
-
BA
-
Bari, BA, Italien, 70124
- "Giovanni Paolo II" Oncology Institute
-
Bari, BA, Italien
- "San Paolo Hospital" Oncology Service
-
-
BN
-
Benevento, BN, Italien
- Division of Medical Oncology, "Fatebenefratelli" Hospital
-
-
BR
-
Brindisi, BR, Italien, 72100
- Division of Medical Oncology, "Sen. Perrino" Hospital, Brindisi, Italy
-
-
FG
-
San Giovanni Rotondo, FG, Italien
- 7 Division of Medical Oncology, "Casa Sollievo della Sofferenza" Hospital,
-
-
Le
-
Lecce, Le, Italien
- Medical Oncology Division "Vito Fazzi" Hospital
-
-
PA
-
Palermo, PA, Italien
- Division of Medical Oncology, "Buccheri-La Ferla" Hospital
-
Palermo, PA, Italien
- Division of Medical Oncology, "La Maddalena" Hospital
-
-
TA
-
Castellaneta, TA, Italien
- Division of Medical Oncology, Castellaneta Hospital
-
Taranto, TA, Italien
- Division of Medical Oncology "San Giuseppe Moscati Hospital"
-
-
VE
-
Mirano, VE, Italien
- Clinical Trials Office, Department of Medical Sciences, Azienda ULSS 13
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Written informed consent(as approved by the local Ethical Committee)
- Histological type consisting mainly of non-squamous histology defined preferably with stage IV metastatic disease or stage IIIB in the presence of supraclavicular lymph nodes according to the parameters of TNM 7th Ed, not amenable to curative therapy
- ECOG PS 0-1
- Adequate bone marrow reserve
- Adequate hepatic, coagulative and renal function
Exclusion Criteria:
- Mixed NSCLC tumors or mixed adenosquamous carcinomas with a predominant squamous component histotype (NSCLC and SCLC) or adenosquamous forms, with predominant squamous component
- History of gross hemoptysis <3 months prior to enrollment or history or evidence of inherited bleeding diathesis or coagulopathy with the risk of bleeding.
- Tumors invading or abutting major blood vessels (based on radiologist assessment)
- Evidence of brain metastases not previously treated with RT (or any loco-regional treatment)
- Prior neoadjuvant or adjuvant chemotherapy within six months prior to study enrollment
- Previous radiotherapy in the last month before study entry (except for radiotherapy to symptomatic bone sites at risk and not covered in the premises of measurable disease and assessable)
- A major surgery (including open biopsy) in the month preceding study enrollment or anticipation of a major surgery during the study
- Unable or unwilling to take folic acid or vitamin B12 supplementation
- Unable or unwilling to take corticosteroids
- History of gastrointestinal fistula, perforation, or abscess, inflammatory bowel disease, or diverticulitis
- Clinically significant third-space fluid collections, for example, ascites or pleural effusions that cannot be controlled by drainage or other procedures prior to study entry
- Need for taking or have recently taken (within 10 days of enrollment) aspirin (>325 mg/d), clopidogrel at doses >75 mg/d, dipyramidole, ticlopidine, or cilostazol. Patients are also excluded if they cannot hold nonsteroidal anti-inflammatory agents, other than prophylactic therapy with low-dose aspirin, for a 5-day period during each cycle (8-day period for long-acting agents, such as piroxicam)
- Need for taking or have recently taken (within 10 days of enrollment) fulldose oral or parenteral anticoagulants or thrombolytic agents for therapeutic purposes. Prophylactic use of anticoagulants is allowed; international normalized ratio (INR) should be <1.5 at study enrollment
- History of thrombotic disorders within the last 6 months prior to entry History of hypertension, unless hypertension is well controlled study entry (≤150/90 mm Hg) and the patient is on a stable regimen of antihypertensive therapy. Patients should not have any prior history of hypertensive crisis or hypertensive encephalopathy
- Serious cardiac condition, such as myocardial infarction within 6 months, angina, or heart disease, as defined by the New York Heart Association Class III or IV
- Serious concomitant systemic disorder (for example, active infection including human immunodeficiency virus) that, in the opinion of the investigator, would compromise the patient's ability to adhere to the protocol
- Receiving concurrent administration of any other antitumor therapy
- Have a second primary malignancy that is clinically detectable at the time of consideration for study enrollment
- Have had a prior malignancy other than NSCLC, carcinoma in situ of the cervix, or nonmelanoma skin cancer, unless that prior malignancy was diagnosed and definitively treated at least 5 years previously with no subsequent evidence of recurrence. Patients with a history of low grade (Gleason score ≤6) localized prostate cancer will be eligible even if diagnosed less than 5 years previously
- Patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Aktiv komparator: Cisplatin and Pemetrexed
|
Cisplatin 75 mg / m2 d1 with Pemetrexed 500 mg / m2 d1 every 3 weeks for 6 cycles followed (in responding or stable patients) by Pemetrexed 500 mg / m2 every 3 weeks, until progression or unacceptable toxicity
|
Aktiv komparator: Carboplatin paclitaxel bevacizumab
|
Carboplatin AUC 6 d1 plus Paclitaxel 200 mg/m2 d1 and Bevacizumab 15 mg/kg every 3 weeks for 6 cycles followed in stable or responding patients by Bevacizumab 15 mg/kg every 3 weeks, until progression or unacceptable toxicity
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
Difference in terms of quality of life (QOL) between treatment arms
Tidsram: Treatment efficacy will be evaluated at baseline and every 3 cycles during chemo period and every two months during the maintenance phase
|
Treatment efficacy will be evaluated at baseline and every 3 cycles during chemo period and every two months during the maintenance phase
|
Sekundära resultatmått
Resultatmått |
Tidsram |
---|---|
treatment activity in terms of response rate
Tidsram: Two year
|
Two year
|
toxicity evaluation
Tidsram: Two years
|
Two years
|
Evaluation of QoL across time
Tidsram: Two years
|
Two years
|
Samarbetspartners och utredare
Utredare
- Huvudutredare: Giuseppe Colucci, MD, Oncology Institute of Bari
- Studierektor: Domenico Galetta, MD, "Giovanni Paolo II" Oncology Instutute Medical Oncology Dept. Bari (Italy)
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Förväntat)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Luftvägssjukdomar
- Neoplasmer
- Lungsjukdomar
- Neoplasmer efter plats
- Neoplasmer i andningsvägarna
- Thoracic neoplasmer
- Karcinom, bronkogent
- Bronkiella neoplasmer
- Lungneoplasmer
- Karcinom, icke-småcellig lunga
- Läkemedels fysiologiska effekter
- Molekylära mekanismer för farmakologisk verkan
- Nukleinsyrasynteshämmare
- Enzyminhibitorer
- Antineoplastiska medel
- Tubulin modulatorer
- Antimitotiska medel
- Mitosmodulatorer
- Antineoplastiska medel, fytogena
- Antineoplastiska medel, immunologiska
- Angiogeneshämmare
- Angiogenesmodulerande medel
- Tillväxtämnen
- Tillväxthämmare
- Folsyraantagonister
- Karboplatin
- Paklitaxel
- Bevacizumab
- Pemetrexed
Andra studie-ID-nummer
- Goim 2903
- 2009-015807-19 (EudraCT-nummer)
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Non-squamous Nonsmall Cell Neoplasm of Lung
-
Case Comprehensive Cancer CenterHar inte rekryterat ännuLymfom, follikulärt | Kutant T-cellslymfom | Non Hodgkin lymfom | Lymfom, storcelligt, anaplastiskt | Lymfomatoid papulos | Mycosis Fungoides of Skin (Diagnos)Förenta staterna
-
Mayo ClinicNational Cancer Institute (NCI)RekryteringÅterkommande Hodgkin-lymfom | Refraktärt Hodgkin-lymfom | Refraktärt plasmacellsmyelom | Återkommande histiocytisk och dendritisk cellneoplasma | Återkommande non-Hodgkin lymfom | Refractory Histiocytic and Dendritic Cell Neoplasm | Refraktärt non-Hodgkin lymfom | Återkommande plasmacellsmyelomFörenta staterna
-
University of California, San FranciscoAvslutadRefraktärt plasmacellsmyelom | Återkommande diffust stort B-cellslymfom | Refraktärt diffust stort B-cellslymfom | Återkommande plasmacellsmyelom | Återkommande malign neoplasm | Refraktär malign neoplasm | Återkommande höggradigt B-cellslymfom | Refraktärt höggradigt B-cellslymfom | Återkommande aggressivt... och andra villkorFörenta staterna
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI); National Heart, Lung, and Blood Institute...AvslutadHematopoetisk och lymfoid cellneoplasma | Diffust stort B-cellslymfom | Refraktärt Hodgkin-lymfom | Waldenström Makroglobulinemi | Mantelcellslymfom | Plasmacellmyelom | Refraktär kronisk lymfatisk leukemi | Myelodysplastisk/myeloproliferativ neoplasma | Kronisk fas Kronisk myelogen leukemi, BCR-ABL1 positiv och andra villkorFörenta staterna, Tyskland, Italien
-
Mustang BioAnmälan via inbjudanDiffust stort B-cellslymfom | Blastisk Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Hårig cell leukemi | Mantelcellslymfom återkommande | Mantelcellslymfom refraktärt | Kronisk lymfatisk leukemi vid återfall | Litet lymfocytiskt lymfom, återfall | Waldenströms makroglobulinemi återkommande | Follikulärt... och andra villkorFörenta staterna
-
University Hospital Southampton NHS Foundation...University of SouthamptonAktiv, inte rekryterandeLivmoderhalscancer | Äggledarneoplasmer | Äggstockscancer | Äggledarcancer | Bröstneoplasma | Endometriella neoplasmer | Vulvarcancer | Vulva neoplasmer | Endometriecancer | Diffust stort B-cellslymfom | Ovarial neoplasm | Bröstcancer Kvinna | Primärt peritonealt karcinom | NonHodgkin lymfom | Cervikal neoplasm | Non-Hodgkins... och andra villkorStorbritannien
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI); National Heart, Lung, and Blood Institute...AvslutadÅterkommande Hodgkin-lymfom | Återkommande akut myeloid leukemi hos vuxna | Återkommande mantelcellslymfom | Waldenström Makroglobulinemi | Kronisk lymfatisk leukemi | Non-Hodgkin lymfom | Återkommande akut lymfatisk leukemi hos vuxna | Återkommande akut lymfatisk leukemi hos barn | Återkommande akut myeloid... och andra villkorFörenta staterna
-
Mayo ClinicNational Cancer Institute (NCI)AvslutadDiffust stort B-cellslymfom | Mjältens marginalzon lymfom | Mantelcellslymfom | Mycosis Fungoides | Sezary syndrom | Lymfoplasmacytiskt lymfom | Anaplastiskt storcelligt lymfom | Blastisk Plasmacytoid Dendritic Cell Neoplasm | Primärt effusionslymfom | Vuxen T-cellsleukemi/lymfom | Lymfoproliferativ störning... och andra villkorFörenta staterna
-
Fred Hutchinson Cancer CenterNational Cord Blood NetworkRekryteringAkut myeloid leukemi | Akut lymfoblastisk leukemi | Non-Hodgkin lymfom | Myelodysplastiskt syndrom | Neoplasma i hematopoetiska och lymfoida systemet | Blastisk Plasmacytoid Dendritic Cell Neoplasm | Myeloproliferativ neoplasma | Akut leukemi av tvetydig härstamning | Blandad fenotyp Akut leukemi | Kronisk...Förenta staterna
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)AvslutadAkut myeloid leukemi | Hodgkins lymfom | Waldenström Makroglobulinemi | Akut lymfoblastisk leukemi | Kronisk lymfatisk leukemi | Non-Hodgkin lymfom | Plasmacellmyelom | Myelodysplastisk/myeloproliferativ neoplasma | Graft kontra värdsjukdom | Kronisk myelogen leukemi, BCR-ABL1 positivFörenta staterna, Italien
Kliniska prövningar på cisplatin pemetrexed
-
CanBas Co. Ltd.AvslutadFasta tumörer | Malignt pleuralt mesoteliomFörenta staterna
-
CanBas Co. Ltd.AvslutadMetastaserad icke-småcellig lungcancerFörenta staterna
-
BayerAvslutadSmåcelligt lungkarcinomFörenta staterna
-
PfizerAvslutadNSCLC (icke-småcellig lungcancer)Hong Kong, Kina, Taiwan, Malaysia, Thailand
-
Yonsei UniversityAktiv, inte rekryterandeSarkomKorea, Republiken av
-
Eli Lilly and CompanyAvslutadGastrointestinala neoplasmerKorea, Republiken av
-
BeiGeneAvslutad
-
Yonsei UniversityRekrytering
-
Eli Lilly and CompanyAvslutadMalignt pleuralt mesoteliomJapan
-
Shanghai Chest HospitalAvslutadLungadenokarcinom | EGFR-aktiverande mutation